NeoDecoNCT05993442
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Final enrollment: 1379 participants (planned 3080)
Notable Primary completion date: Sep 2025 to Apr 2026v5 Show 7 more changesShow less
- Eligibility criteria expanded, about 9 words
- Primary endpoints: 2 to 1
- Study sites: 10 to 24
- Study completion date: Mar 2026 to May 2026
- Secondary endpoints: 2 to 9
- Study description expanded, about 126 words
- Collaborators reordered
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 8 more changesShow less
- Enrollment target: 11440 to 3080
- Primary completion date: Feb 2025 to Sep 2025
- Study sites: 0 to 10
- Study completion date: Sep 2026 to Mar 2026
- Start date changed from estimate of Feb 2024 to May 28, 2024
- Study description expanded, about 46 words
- Collaborators: 6 to 7
- Study title shortened, about 2 words
Notable Primary completion date: Feb 2024 to Feb 2025v3 Show 7 more changesShow less
- Start date: Nov 2023 to Feb 2024
- Eligibility criteria expanded, about 23 words
- Study completion date: Aug 2025 to Sep 2026
- Interventions: Optimising kangaroo care (Behavioral) to Optimised kangaroo care (Behavioral)
- Study description shortened, about 59 words
- Collaborators expanded, about 24 words
- Study title expanded, about 5 words
- Minor Secondary endpoints: details revised at 2 of 2 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
The sites randomised in this group will adapt the study intervention consisting of: Component 1: Skin-to-skin contact for optimised KC, describes the targeted level of early, repeated and sustained skin-to-skin contact (StSC) considered to represent optimised KC in a high-technology neonatal unit environment in which KC is already offered as part of routine care. Component 2: Implementation Support aims to engage clinical staff in the neonatal unit who are involved in implementing StSC as part of optimised KC.
The sites randomised in this group will follow the standard care, including KC and StSC sessions, treatment of severe infections/sepsis and infection prevention and control measures based on current routine local practice. Standard care in all participating NICUs already includes KC but without specific activities to ensure this is implemented according to international best practice recommendations.
Behavioral: Optimised kangaroo care
Sites
24 sites in 5 countries
Greece 7, Switzerland 5, United Kingdom 5, Italy 4, Spain 3